Novel GPR120 Agonists with Improved Pharmacokinetic Profiles for the Treatment of Type 2 Diabetes

GPR120 is a promising target for the treatment of type 2 diabetes (T2DM), which is activated by free fatty acids (FFAs) and stimulates the release of glucagon-like peptide-1(GLP-1). GLP-1, as an incretin, can enhance glucose-dependent secretion of insulin from pancreatic beta cells and reduce blood...

Descripción completa

Detalles Bibliográficos
Autores principales: Ji, Guoxia, Guo, Qinghua, Xue, Qidi, Kong, Ruifang, Wang, Shiben, Lei, Kang, Liu, Renmin, Wang, Xuekun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8624523/
https://www.ncbi.nlm.nih.gov/pubmed/34833999
http://dx.doi.org/10.3390/molecules26226907

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8624523/
https://www.ncbi.nlm.nih.gov/pubmed/34833999
http://dx.doi.org/10.3390/molecules26226907

Ejemplares similares